ArticleMetabolic brain disease2018
Idalopirdine, a selective 5-HT
Article in Metabolic brain disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 40 citations in OpenAlex.
- Perspectives on obesity imaging: [International journal of obesity (2005) · 2025Article
- Impact of Antidepressants on Weight Gain: Underlying Mechanisms and Mitigation Strategies.Archives of clinical and biomedical research · 2025Article
- The Effect of KSK-94, a Dual Histamine HPharmaceuticals (Basel, Switzerland) · 2024Article
- WAY-208466, a 5-HTNeuroscience applied · 2024Article
- Impact of 5-HTCells · 2023Review
- Selective 5-HTPharmaceuticals (Basel, Switzerland) · 2023Article
- KSK-74: Dual Histamine HInternational journal of molecular sciences · 2022Article
- Histamine HPharmaceuticals (Basel, Switzerland) · 2021Article
- The Phenoxyalkyltriazine Antagonists for 5-HTInternational journal of molecular sciences · 2021Article
- Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia.Journal of medicinal chemistry · 2021Article
- NovelPharmaceuticals (Basel, Switzerland) · 2021Article
- Effects of GPR18 Ligands on Body Weight and Metabolic Parameters in a Female Rat Model of Excessive Eating.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Dietary restriction of amino acids for Cancer therapy.Nutrition & metabolism · 2020Review
- Are the Hydantoin-1,3,5-triazine 5-HTMolecules (Basel, Switzerland) · 2019Article
- The 1,3,5-Triazine Derivatives as Innovative Chemical Family of 5-HTInternational journal of molecular sciences · 2019Article
- Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT₆ Serotonin Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo.Molecules (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity, from early childhood onwards, is a common societal problem. The overconsumption of sweet, salty and high-fat products are the main factors that cause excessive weight gain. It is therefore necessary to search for new drugs that affect satiety centers and reduce the sense of hunger and caloric intake. It has been suggested that the blockade of 5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.